<DOC>
	<DOCNO>NCT00941109</DOCNO>
	<brief_summary>The purpose study determine body absorbs decitabine take orally patient Myelodysplastic Syndrome ( MDS ) . Safety also assess oral dose .</brief_summary>
	<brief_title>Escalation Study Determine Bioavailability Single Oral Dose Decitabine Patients With Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Cohorts dose sequentially , escalation may stop 5th cohort dose . Each cycle approximately 4 week length . Following Cycle 1 , patient may receive additional 4 follow-up cycle decitabine . Cycles 2-5 include 20 mg/m^2 1-hour IV infusion decitabine Days 1-5 cohort .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Histologically confirm de novo secondary MDS . 2 . Age great equal 18 year . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . 4 . Adequate renal hepatic function ( creatinine less equal 2.0 mg/dL , total bilirubin le 2.0 mg/dL , aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] less 3 time upper limit normal ) . 5 . Life expectancy least 6 week . 6 . If currently receive 5 day decitabine regimen , patient must schedule receive one cycle 5 day decitabine . 7 . Recovered toxic effect prior therapy entry study . 8 . Women childbearing potential men must agree practice medically approve form contraception ( one follow must use : condom [ male female ] spermicidal agent , diaphragm cervical cap spermicidal agent , intrauterine device , hormonal contraception , abstinence ) course study 2 month follow last dose decitabine . 1 . Candidates front high dose induction chemotherapy . MDS patient schedule receive decitabine prior bone marrow transplant stem cell transplant allow . 2 . History treatment failure decitabine . 3 . Received experimental agent within precede 30 day prior screen . 4 . Uncontrolled cardiac pulmonary disease . 5 . History intestinal surgery , pancreatic surgery , gastric surgery . 6 . Any clinically relevant disease , disorder ( include psychiatric disorder ) , condition , opinion Investigator , may interfere objective study , especially gastrointestinal ( GI ) absorption study drug , and/or safety subject study . 7 . Current active colitis etiology ( Clostridium difficile colitis , ulcerative colitis , Crohn 's disease , etc . ) recent ( less 2 week ) episode colitis . 8 . Pregnant lactating . Female patient childbearing potential must negative serum pregnancy test screen negative urine pregnancy test Day 1 prior dose . 9 . Known positive serology human immunodeficiency virus ( HIV ) . 10 . Active viral , fungal , bacterial infection . No patient may enter study unless infection fully treat .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>MDS</keyword>
</DOC>